

SATRALIZUMAB

BRAND NAME	ENSPRYNG
DRUG CLASS	Immunosuppressant, monoclonal antibody (human)
AVAILABILITY	Prefilled syringe contains 120 mg/1 mL of satralizumab. Also contains histidine, aspartic acid, arginine and poloxamer 188. ¹ The solution is clear and colourless to slightly yellow. ¹
pH	No information
PREPARATION	Ready to use. Allow the syringe to reach room temperature. ² Do not shake. ¹
STABILITY	Store at 2 to 8 °C. Do not freeze. Protect from light. ¹ The syringe may be taken out of the fridge and returned, if unopened and kept in the box. Stable for a composite total of 8 days below 30 °C. ¹
ADMINISTRATION	
IM injection	Not recommended
SUBCUT injection	Inject into the abdomen or thigh. Rotate the site of injection. ¹ The first dose must be given under medical supervision. Subsequent doses may be suitable for self-administration after appropriate training. ¹
IV injection	Not recommended
IV infusion	Not recommended
COMPATIBILITY	No information
INCOMPATIBILITY	No information
SPECIAL NOTES	Injection site reactions are usually mild to moderate and include pain, flushing, redness, itching and rash. ¹

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 24/03/2022.
2. Consumer medicine information. Available from www.tga.gov.au. Accessed 24/03/2022.